AIRLINK 156.12 Increased By ▲ 0.74 (0.48%)
BOP 10.01 Increased By ▲ 0.32 (3.3%)
CNERGY 7.05 Decreased By ▼ -0.06 (-0.84%)
CPHL 84.13 Increased By ▲ 0.06 (0.07%)
FCCL 44.65 Increased By ▲ 1.21 (2.79%)
FFL 14.89 Increased By ▲ 0.10 (0.68%)
FLYNG 33.34 Increased By ▲ 3.03 (10%)
HUBC 135.55 Decreased By ▼ -0.69 (-0.51%)
HUMNL 12.82 Increased By ▲ 0.31 (2.48%)
KEL 4.16 Increased By ▲ 0.14 (3.48%)
KOSM 5.07 Increased By ▲ 0.05 (1%)
MLCF 71.60 Increased By ▲ 2.16 (3.11%)
OGDC 200.22 Decreased By ▼ -3.03 (-1.49%)
PACE 5.05 Decreased By ▼ -0.01 (-0.2%)
PAEL 43.89 Increased By ▲ 1.39 (3.27%)
PIAHCLA 16.74 Increased By ▲ 0.17 (1.03%)
PIBTL 8.71 Decreased By ▼ -0.08 (-0.91%)
POWER 14.91 Increased By ▲ 0.98 (7.04%)
PPL 148.48 Decreased By ▼ -2.35 (-1.56%)
PRL 29.55 Increased By ▲ 0.64 (2.21%)
PTC 20.85 Increased By ▲ 0.12 (0.58%)
SEARL 83.47 Decreased By ▼ -0.57 (-0.68%)
SSGC 40.03 Decreased By ▼ -0.22 (-0.55%)
SYM 14.88 Increased By ▲ 0.05 (0.34%)
TELE 6.99 Increased By ▲ 0.01 (0.14%)
TPLP 8.38 Increased By ▲ 0.11 (1.33%)
TRG 63.63 Decreased By ▼ -0.42 (-0.66%)
WAVESAPP 8.87 Increased By ▲ 0.30 (3.5%)
WTL 1.34 Increased By ▲ 0.07 (5.51%)
YOUW 3.46 Increased By ▲ 0.04 (1.17%)
AIRLINK 156.12 Increased By ▲ 0.74 (0.48%)
BOP 10.01 Increased By ▲ 0.32 (3.3%)
CNERGY 7.05 Decreased By ▼ -0.06 (-0.84%)
CPHL 84.13 Increased By ▲ 0.06 (0.07%)
FCCL 44.65 Increased By ▲ 1.21 (2.79%)
FFL 14.89 Increased By ▲ 0.10 (0.68%)
FLYNG 33.34 Increased By ▲ 3.03 (10%)
HUBC 135.55 Decreased By ▼ -0.69 (-0.51%)
HUMNL 12.82 Increased By ▲ 0.31 (2.48%)
KEL 4.16 Increased By ▲ 0.14 (3.48%)
KOSM 5.07 Increased By ▲ 0.05 (1%)
MLCF 71.60 Increased By ▲ 2.16 (3.11%)
OGDC 200.22 Decreased By ▼ -3.03 (-1.49%)
PACE 5.05 Decreased By ▼ -0.01 (-0.2%)
PAEL 43.89 Increased By ▲ 1.39 (3.27%)
PIAHCLA 16.74 Increased By ▲ 0.17 (1.03%)
PIBTL 8.71 Decreased By ▼ -0.08 (-0.91%)
POWER 14.91 Increased By ▲ 0.98 (7.04%)
PPL 148.48 Decreased By ▼ -2.35 (-1.56%)
PRL 29.55 Increased By ▲ 0.64 (2.21%)
PTC 20.85 Increased By ▲ 0.12 (0.58%)
SEARL 83.47 Decreased By ▼ -0.57 (-0.68%)
SSGC 40.03 Decreased By ▼ -0.22 (-0.55%)
SYM 14.88 Increased By ▲ 0.05 (0.34%)
TELE 6.99 Increased By ▲ 0.01 (0.14%)
TPLP 8.38 Increased By ▲ 0.11 (1.33%)
TRG 63.63 Decreased By ▼ -0.42 (-0.66%)
WAVESAPP 8.87 Increased By ▲ 0.30 (3.5%)
WTL 1.34 Increased By ▲ 0.07 (5.51%)
YOUW 3.46 Increased By ▲ 0.04 (1.17%)
BR100 12,149 Decreased By -11.3 (-0.09%)
BR30 35,394 Increased By 37.7 (0.11%)
KSE100 114,102 Decreased By -11.7 (-0.01%)
KSE30 34,809 Decreased By -108.8 (-0.31%)

KARACHI: The Pakistan Chemist and Druggist Association (PCDA) has raised serious concerns over the imposition of infrastructure cess at the import stage, imposed by the Excise, Taxation & Narcotics Control Department of Sindh.

The PCDA emphasised the detrimental impact this levy has on the import of critical pharmaceutical products.

According to the spokesperson of PCDA Abdul Samad Budhani, pharmaceutical imports consist of life-saving medicines crucial for the treatment of critical diseases, including Cardiology, Oncology, Neurology, and Nephrology. Most of these medicines are not manufactured locally, making their import vital to the healthcare sector.

However, he said, due to the escalating costs associated with the infrastructure cess, many pharmaceutical companies have ceased imports, leaving patients vulnerable and worsening the availability of critical medications.

In a letter addressed to the Secretary of Excise, Taxation & Narcotics Control, Sindh, the Senior Vice President of the Federation of Pakistan Chambers of Commerce & Industry (FPCCI), Saquib Fayyaz Magoon, highlighted the urgency of the situation.

He emphasized the need for a review of the Sindh Development and Infrastructure Cess 2017, which, according to stakeholders, has made the import of finished medicines commercially unviable.

The issue was also previously raised in a letter dated February 27, 2024, but remains unresolved.

“The availability of essential imported medicines is already shrinking, causing grave concerns for patients who rely on these treatments. In the better interest of sustaining medical practices in Pakistan, it is imperative to find a solution,” Magoon stated.

The FPCCI has requested the department to hold a personal hearing with representatives from the PCDA to discuss the issue further and develop a comprehensive strategy to address the matter. The association awaits a response from the Excise Department, hoping for a timely resolution to avert a potential healthcare crisis.

This development comes at a time when the pharmaceutical industry is already grappling with supply chain disruptions and increasing production costs, making the removal or adjustment of such levies crucial to the industry’s survival.

Copyright Business Recorder, 2024

Comments

Comments are closed.